45.46
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo Finance
Exact Sciences (EXAS): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential - Insider Monkey
Liquid Biopsy in Cancer Diagnostics Market to Grow at a CAGR of ~17% by 2032 with Advancements in Non-Invasive Testing | DelveInsight - GlobeNewswire Inc.
EXAS Quantitative Stock AnalysisBenjamin Graham - Nasdaq
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic By Stocktwits - Investing.com India
Exact Sciences Launches New Test To Monitor Cancer Recurrence: Retail’s Optimistic - MSN
Exact Sciences launches the Oncodetect MRD test - TipRanks
Exact Sciences (EXAS) Launches Oncodetect Test for Enhanced Cancer Care | EXAS Stock News - GuruFocus
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test | EXAS Stock News - GuruFocus
Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test - Yahoo Finance
Market Sentiment Around Loss-Making Exact Sciences Corporation (NASDAQ:EXAS) - simplywall.st
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers - Yahoo Finance
Exact Sciences (EXAS) Validates Oncotype DX Test for Diverse Bre - GuruFocus
JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups - The Joplin Globe
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings) - Benzinga
Mizuho Initiates Exact Sciences at Outperform With $60 Price Target - marketscreener.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform - Investing.com
Mizuho sets $60 target on Exact Sciences stock, sees outperform By Investing.com - Investing.com UK
Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.
10 Promising Biotech Stocks to Invest in (April 2025) - Securities.io
Exact Sciences Schedules First Quarter 2025 Earnings Call - The Joplin Globe
Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening - BioSpace
Benchmark maintains Buy on Exact Sciences, price target at $65 By Investing.com - Investing.com South Africa
Benchmark maintains Buy on Exact Sciences, price target at $65 - Investing.com
Exact Sciences Positioned for Growth with Upcoming Product Launches and Margin Expansion - TipRanks
High Growth Tech Stocks To Watch In The US March 2025 - Yahoo Finance
Should You Retain Exact Sciences Stock in Your Portfolio Now? - Yahoo Finance
Why Exact Sciences Corporation (EXAS) is Among the Best Diagnostics Stocks to Invest in Right Now - Insider Monkey
12 Best Diagnostics Stocks to Invest In Right Now - Insider Monkey
Exact Sciences (EXAS) Down 10.6% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Invest in Exact Sciences Corp. (EXAS)? - MSN
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN - Quantisnow
Former Exact Sciences COO Joins Sera Prognostics Board Amid Strategic Expansion - Stock Titan
"Pick Up Your Poop" F Cancer's New Campaign Encourages At-Home Colorectal Cancer Screening - WV News
RBC Capital Initiates Coverage of Exact Sciences (BMV:EXAS) with Sector Perform Recommendation - Nasdaq
Commit To Buy EXACT Sciences At $30, Earn 14% Using Options - Nasdaq
Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts - Benzinga
PreventionGenetics Assumes the Management of Sponsored Genetic Testing Program for Three Rare Genetic Diseases: Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1 & Hereditary ATTR Amyloidosis - Business Wire
Exact Sciences initiated with a Sector Perform at RBC Capital - TipRanks
Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner - Joplin Globe
Exact Sciences Triples Industry Average in Employee Engagement, Wins Prestigious Gallup Award - StockTitan
New Data Highlight the Positive Impact of Exact Sciences’ Oncotype DX - Business Wire
Charles Schwab Investment Management Inc. Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Co. (NASDAQ:EXAS) Stake Increased by Jones Financial Companies Lllp - Defense World
3 Top Cancer Biotechs to Keep An Eye On in 2025 - Yahoo Finance
Exact Sciences at Raymond James Conference: Strategic Growth and Innovation - Investing.com
La Paloma CC: Set to host PGA Tour Champions' Cologuard Classic - The First Call
LA PALOMA COUNTRY CLUB SET TO HOST 2025 COLOGUARD CLASSIC BY EXACT SCIENCES - The Golf Wire
Here’s What Led Artisan Mid Cap Fund to Trim Exact Sciences Corporation (EXAS) - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):